Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

April 20, 2020 Issue

09815-cover-opener.jpg

April 20, 2020 Cover

Volume 98, Issue 15

The presence of the probable carcinogen has prompted drugmakers to issue recall after recall. What risk does it pose, what’s the chemistry behind it, and how are drugmakers going to stop the contamination?

Cover image:The presence of the potential carcinogen NDMA in common drugs has triggered waves of recalls. What are drugmakers doing to address the problem?


Credit: Chris Gash

Full Article
Pharmaceutical Chemicals

NDMA, a contaminant found in multiple drugs, has industry seeking sources and solutions

The presence of the probable carcinogen has prompted drugmakers to issue recall after recall. What risk does it pose, what’s the chemistry behind it, and how are drugmakers going to stop the contamination?

  • Consortia lend their supercomputers to fight COVID-19

    National labs, universities, and companies around the world are fast-tracking proposals to use their high-performance computer resources against the novel coronavirus

  • Get ready for a potential chemistry job crisis

    Whatever COVID-19 does to chemical employment, it’s wise to start preparing your career emergency kit

  • Environmental toxicologist wants to understand how microplastics affect human health

    Stephanie Wright of King’s College London discusses what’s known about microplastics and how much more there is to learn

ADVERTISEMENT
image name
Vaccines

COVID-19 vaccines are moving toward clinical trials

Tests of 10 or more novel vaccines could be underway by mid-May

ADVERTISEMENT
ADVERTISEMENT